Kamada Ltd(NASDAQ:KMDA) 
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Al...
Website: http://www.kamada.com
Founded: 1990
Full Time Employees: 429
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-05-17 | 2021-12-31 | 2021-09-30 | 2021-05-12 | 2020-03-31 | 2020-02-12 | 2019-12-31 | 2019-11-13 | 2019-09-30 | 2019-08-06 | 2019-06-30 | 2019-05-14 | 2019-03-31 | 2019-02-12 | 2018-12-31 | 2018-11-13 | 2018-09-30 | 2018-08-07 | 2018-06-30 | 2018-05-15 | 2018-03-31 | 2018-02-07 | 2017-12-31 | 2017-11-13 | 2017-09-30 | 2017-08-01 | 2017-06-30 | 2017-03-31 | 2017-02-06 | 2016-12-31 | 2016-11-10 | 2016-09-30 | 2016-08-02 | 2016-02-02 | 2015-12-31 | 2015-02-11 | 2014-12-31 | 2014-02-05 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||||||||||||||||||||||||||||||||||
current assets | |||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 71,997 | 65,985 | 76,250,000 | 78,435,000 | 72,001,000 | 56,547 | 48,194 | 55,641,000 | 52,603 | 34,258,000 | 31,252,000 | 29,933,000 | 21,967,000 | 18,587,000 | 99,840,000 | 61,436,000 | 49,288,000 | 42,662,000 | 42,662,000 | 27,449,000 | 27,449,000 | 23,835,000 | 23,835,000 | 22,037,000 | 22,037,000 | 18,093,000 | 18,093,000 | 12,871,000 | 12,871,000 | 12,356,000 | 12,356,000 | 17,497,000 | 17,497,000 | 12,681,000 | 12,681,000 | 12,156,000 | 12,156,000 | 11,024,000 | 11,024,000 | 10,778,000 | 9,968,000 | 9,968,000 | 6,476,000 | 6,476,000 | 7,136,000 | 5,047,000 | 5,047,000 | 14,546,000 | 14,546,000 | 59,110,000 | 59,110,000 |
trade receivables | 31,379 | 30,501 | 27,876,000 | 21,547,000 | 16,295,000 | 26,228 | 18,855 | 19,877,000 | 25,107 | 27,252,000 | 23,997,000 | 17,738,000 | 21,568,000 | 35,162,000 | 26,548,000 | 20,367,000 | 26,266,000 | 23,210,000 | 23,210,000 | 23,999,000 | 23,999,000 | 25,497,000 | 25,497,000 | 23,210,000 | 23,210,000 | 27,674,000 | 27,674,000 | 14,826,000 | 14,826,000 | 24,779,000 | 24,779,000 | 17,083,000 | 17,083,000 | 30,662,000 | 30,662,000 | 21,980,000 | 21,980,000 | 22,778,000 | 22,778,000 | 10,849,000 | 19,788,000 | 19,788,000 | 14,501,000 | 14,501,000 | 15,936,000 | 23,071,000 | 23,071,000 | 17,993,000 | 17,514,000 | 17,882,000 | 17,882,000 |
other accounts receivables | 3,945 | 4,704 | 6,016,000 | 5,546,000 | 4,555,000 | 4,940 | 6,411 | 5,965,000 | 1,648 | 8,710,000 | 6,884,000 | 6,410,000 | 7,867,000 | 8,872,000 | 4,392,000 | 4,091,000 | 1,736,000 | 3,272,000 | 3,272,000 | 1,722,000 | 1,722,000 | 3,292,000 | 3,292,000 | 3,442,000 | 3,442,000 | 3,308,000 | 3,308,000 | 1,857,000 | 1,857,000 | 1,863,000 | 1,863,000 | 2,027,000 | 2,027,000 | 2,132,000 | 2,132,000 | 2,683,000 | 2,683,000 | 2,087,000 | 2,087,000 | 2,930,000 | 3,063,000 | 3,063,000 | 4,022,000 | 4,022,000 | 3,475,000 | 2,881,000 | 2,881,000 | 2,359,000 | 2,359,000 | 3,694,000 | 3,694,000 |
inventories | 85,413 | 82,079 | 78,358,000 | 78,819,000 | 71,558,000 | 78,713 | 84,348 | 88,479,000 | 73,795 | 68,785,000 | 73,029,000 | 64,520,000 | 64,761,000 | 67,423,000 | 48,163,000 | 41,155,000 | 41,787,000 | 43,173,000 | 43,173,000 | 34,031,000 | 34,031,000 | 35,501,000 | 35,501,000 | 31,708,000 | 31,708,000 | 29,316,000 | 29,316,000 | 28,934,000 | 28,934,000 | 27,373,000 | 27,373,000 | 28,175,000 | 28,175,000 | 21,070,000 | 21,070,000 | 23,144,000 | 23,144,000 | 24,072,000 | 24,072,000 | 27,677,000 | 25,594,000 | 25,594,000 | 28,086,000 | 28,086,000 | 28,423,000 | 26,336,000 | 26,336,000 | 25,423,000 | 25,423,000 | 21,933,000 | 21,933,000 |
total current assets | 192,734 | 183,269 | 188,500,000 | 184,347,000 | 164,409,000 | 166,428 | 157,808 | 169,962,000 | 153,153 | 139,005,000 | 135,162,000 | 118,601,000 | 116,163,000 | 130,044,000 | 178,943,000 | 175,087,000 | 166,201,000 | 143,562,000 | 143,562,000 | 126,581,000 | 126,581,000 | 126,247,000 | 110,890,000 | ||||||||||||||||||||||||||||
non-current assets | |||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment | 38,100 | 37,894 | 37,406,000 | 36,245,000 | 33,746,000 | 31,971 | 30,727 | 28,224,000 | 27,362 | 26,157,000 | 25,898,000 | 25,914,000 | 26,098,000 | 26,307,000 | 25,856,000 | 25,492,000 | 24,379,000 | 28,572,000 | 24,550,000 | 28,297,000 | 28,297,000 | 28,424,000 | 28,424,000 | 28,829,000 | 28,829,000 | 25,004,000 | 25,004,000 | 24,406,000 | 24,406,000 | 24,916,000 | 24,916,000 | 25,125,000 | 25,125,000 | 25,178,000 | 25,178,000 | 23,597,000 | 23,597,000 | 23,925,000 | 23,925,000 | 22,655,000 | 22,249,000 | 22,249,000 | 20,720,000 | 20,720,000 | 21,138,000 | 21,309,000 | 21,309,000 | 21,769,000 | 21,769,000 | 21,443,000 | 21,443,000 |
right-of-use assets | 9,189 | 9,250 | 9,539,000 | 9,617,000 | 9,854,000 | 7,552 | 7,632 | 7,761,000 | 5,494 | 2,568,000 | 2,793,000 | 2,810,000 | 2,990,000 | 3,092,000 | 3,479,000 | 3,800,000 | 4,022,000 | ||||||||||||||||||||||||||||||||||
intangible assets and other long-term assets | 99,186 | 101,422,000 | 103,226,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
goodwill | 30,313 | 30,313 | 30,313,000 | 30,313,000 | |||||||||||||||||||||||||||||||||||||||||||||||
contract assets | 7,688 | 7,807 | 7,925,000 | 8,159,000 | 8,257 | 8,384 | 8,546 | 7,164,000 | 6,361,000 | 5,987,000 | 4,987,000 | 3,295,000 | |||||||||||||||||||||||||||||||||||||||
deferred taxes | 1,723 | 659 | 2,061,000 | 488,000 | 939,000 | 1,311,000 | 1,311,000 | 1,445,000 | 1,445,000 | 1,644,000 | 1,644,000 | 1,895,000 | 1,895,000 | 2,048,000 | 2,048,000 | ||||||||||||||||||||||||||||||||||||
total non-current assets | 184,476 | 184,904 | 186,605,000 | 187,908,000 | 186,800,000 | 184,610 | 185,366 | 184,945,000 | 183,903 | 183,374,000 | 184,475,000 | 185,534,000 | 186,933,000 | 188,623,000 | 37,584,000 | 35,441,000 | 30,592,000 | 30,235,000 | 30,235,000 | 29,920,000 | 29,920,000 | 30,242,000 | 27,226,000 | ||||||||||||||||||||||||||||
total assets | 377,210 | 368,173 | 375,105,000 | 372,255,000 | 351,209,000 | 351,038 | 343,174 | 354,907,000 | 337,056 | 322,379,000 | 319,637,000 | 304,135,000 | 303,096,000 | 318,667,000 | 216,527,000 | 210,528,000 | 196,793,000 | 173,797,000 | 173,797,000 | 156,501,000 | 156,501,000 | 156,489,000 | 138,116,000 | ||||||||||||||||||||||||||||
liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||
current maturities of lease liabilities | 1,912 | 1,866 | 1,780,000 | 1,631,000 | 1,586,000 | 1,494 | 1,467 | 1,384,000 | 1,138 | 1,016,000 | 1,004,000 | 1,010,000 | 1,017,000 | 1,154,000 | 1,181,000 | 1,092,000 | 928,000 | 1,020,000 | |||||||||||||||||||||||||||||||||
current maturities of other long term liabilities | 10,585 | 9,850 | 10,889,000 | 10,181,000 | 9,480,000 | 12,610 | 12,980 | 14,996,000 | 15,989 | 29,708,000 | 25,095,000 | 20,117,000 | 19,095,000 | 17,986,000 | |||||||||||||||||||||||||||||||||||||
trade payables | 24,875 | 25,077 | 24,854,000 | 27,735,000 | 14,786,000 | 19,532 | 16,492 | 24,804,000 | 12,812 | 32,917,000 | 30,619,000 | 17,954,000 | 11,682,000 | 25,104,000 | 19,010,000 | 15,076,000 | 18,440,000 | 24,830,000 | 24,830,000 | 13,079,000 | 13,079,000 | 19,879,000 | 19,879,000 | 15,255,000 | 15,255,000 | 17,285,000 | 17,285,000 | 11,512,000 | 11,512,000 | 16,461,000 | 16,461,000 | 16,951,000 | 16,951,000 | 18,036,000 | 18,036,000 | 12,004,000 | 12,004,000 | 14,134,000 | 14,134,000 | 14,648,000 | 16,277,000 | 16,277,000 | 8,916,000 | 8,916,000 | 10,247,000 | 16,917,000 | 16,917,000 | 16,530,000 | 16,530,000 | 14,093,000 | 14,093,000 |
other accounts payables | 9,443 | 8,804 | 19,319,000 | 9,671,000 | 8,104,000 | 7,233 | 6,210 | 8,261,000 | 7,318 | 7,585,000 | 7,948,000 | 6,110,000 | 6,670,000 | 7,142,000 | 6,346,000 | 5,682,000 | 4,875,000 | 5,811,000 | 5,811,000 | 5,439,000 | 5,439,000 | 4,876,000 | 4,876,000 | 4,424,000 | 4,424,000 | 5,261,000 | 5,261,000 | 4,662,000 | 4,662,000 | 4,862,000 | 4,862,000 | 4,912,000 | 4,912,000 | 5,820,000 | 5,820,000 | 6,299,000 | 6,299,000 | 6,772,000 | 6,772,000 | 4,843,000 | 5,614,000 | 5,614,000 | 4,744,000 | 4,744,000 | 6,068,000 | 4,064,000 | 4,064,000 | 4,045,000 | 4,045,000 | 4,313,000 | 4,313,000 |
deferred revenues | 1,022 | 177 | 205,000 | 171,000 | 41,000 | 27 | 26 | 148,000 | 15 | 35,000 | 40,000 | 40,000 | 40,000 | 40,000 | 3,575,000 | 2,525,000 | 649,000 | 589,000 | 589,000 | 561,000 | 561,000 | 461,000 | 461,000 | 461,000 | 461,000 | 461,000 | 461,000 | 1,854,000 | 1,854,000 | 3,073,000 | 3,073,000 | 4,977,000 | 4,977,000 | 4,927,000 | 4,927,000 | 4,816,000 | 4,816,000 | 5,177,000 | 5,177,000 | 4,911,000 | 4,903,000 | 4,903,000 | 4,858,000 | 4,858,000 | 5,114,000 | 1,921,000 | 1,921,000 | 2,821,000 | 2,919,000 | 5,454,000 | 5,454,000 |
total current liabilities | 47,837 | 45,774 | 57,047,000 | 49,389,000 | 33,997,000 | 40,896 | 37,175 | 49,593,000 | 37,272 | 75,705,000 | 69,150,000 | 49,680,000 | 42,229,000 | 54,057,000 | 26,589,000 | 21,977,000 | 25,357,000 | 32,739,000 | 32,739,000 | 20,616,000 | 20,616,000 | 26,656,000 | 23,569,000 | ||||||||||||||||||||||||||||
non-current liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||
lease liabilities | 9,558 | 9,549 | 9,318,000 | 9,431,000 | 9,574,000 | 7,065 | 7,278 | 7,438,000 | 4,717 | 2,177,000 | 2,414,000 | 2,492,000 | 3,056,000 | 3,160,000 | 3,283,000 | 3,417,000 | 3,663,000 | 3,981,000 | |||||||||||||||||||||||||||||||||
contingent consideration | 19,730 | 18,884 | 21,216,000 | 20,646,000 | 17,630,000 | 17,085 | 16,760 | 18,855,000 | 19,642 | 17,534,000 | 20,705,000 | 23,121,000 | 22,551,000 | 21,995,000 | |||||||||||||||||||||||||||||||||||||
other long-term liabilities | 32,539 | 32,782 | 32,990,000 | 32,816,000 | 34,121,000 | 34,238 | 34,842 | 34,379,000 | 36,477 | 37,308,000 | 39,915,000 | 41,304,000 | 42,531,000 | 43,929,000 | |||||||||||||||||||||||||||||||||||||
employee benefit liabilities | 591 | 571 | 516,000 | 509,000 | 618,000 | 602 | 609 | 621,000 | 558 | 672,000 | 813,000 | 764,000 | 1,268,000 | 1,280,000 | 1,467,000 | 1,369,000 | 1,251,000 | 1,269,000 | 1,269,000 | 884,000 | 884,000 | 818,000 | 818,000 | 823,000 | 823,000 | 787,000 | 787,000 | 1,035,000 | 1,035,000 | 1,053,000 | 1,053,000 | 1,130,000 | 1,130,000 | 707,000 | 1,144,000 | 1,000,000 | 1,000,000 | 863,000 | 863,000 | 820,000 | 722,000 | 722,000 | 798,000 | 798,000 | 402,000 | 787,000 | 787,000 | 722,000 | 722,000 | 827,000 | 827,000 |
total non-current liabilities | 64,141 | 62,445 | 66,101,000 | 63,402,000 | 61,943,000 | 58,990 | 59,489 | 61,293,000 | 61,394 | 70,654,000 | 77,936,000 | 82,881,000 | 85,717,000 | 87,786,000 | 8,325,000 | 7,331,000 | 5,621,000 | 5,739,000 | 5,739,000 | 5,744,000 | 5,744,000 | 5,830,000 | 2,171,000 | ||||||||||||||||||||||||||||
shareholder’s equity | |||||||||||||||||||||||||||||||||||||||||||||||||||
ordinary shares | 15,077 | 15,077 | 15,074,000 | 15,028,000 | 15,024,000 | 15,023 | 15,022 | 15,021,000 | 15,020 | 11,734,000 | 11,732,000 | 11,731,000 | 11,728,000 | 11,725,000 | 11,720,000 | 11,713,000 | 11,647,000 | 10,425,000 | 10,425,000 | 10,420,000 | 10,420,000 | 10,418,000 | 10,418,000 | 10,412,000 | 10,412,000 | 10,409,000 | 10,409,000 | 10,406,000 | 10,406,000 | 10,403,000 | 10,403,000 | 10,401,000 | 10,401,000 | 10,400,000 | 10,399,000 | 10,399,000 | 9,321,000 | 9,321,000 | |||||||||||||
additional paid in capital net | 268,222 | 268,243 | 268,160,000 | 266,933,000 | 266,313 | 266,183 | 265,848,000 | 265,700 | 210,495,000 | 210,355,000 | 210,319,000 | 210,269,000 | 210,204,000 | 209,859,000 | 204,702,000 | 180,819,000 | 180,819,000 | 179,147,000 | 179,147,000 | ||||||||||||||||||||||||||||||||
capital reserve due to translation to presentation currency | -3,490 | -3,490 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490 | -3,490 | -3,490,000 | -3,490 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 | -3,490,000 |
capital reserve from hedges | 346 | 456 | -117,000 | 51,000 | 16,000 | -12 | 12 | 140,000 | -98 | -88,000 | -257,000 | -442,000 | 12,000 | 54,000 | 35,000 | 30,000 | 264,000 | 8,000 | 8,000 | 18,000 | 18,000 | 8,000 | 8,000 | 11,000 | 11,000 | -57,000 | -57,000 | -8,000 | -8,000 | -91,000 | -91,000 | -12,000 | -12,000 | 46,000 | 46,000 | 57,000 | 57,000 | 229,000 | 229,000 | 158,000 | -27,000 | -27,000 | 52,000 | 52,000 | 9,000 | -1,000 | -1,000 | -116,000 | -116,000 | 156,000 | 156,000 |
capital reserve from share-based payments | 5,339 | 5,226 | 5,266,000 | 6,316,000 | 6,394,000 | 6,444 | 6,336 | 6,427,000 | 6,198 | 5,505,000 | 5,427,000 | 5,097,000 | 4,771,000 | 4,643,000 | 4,817,000 | 4,674,000 | 8,903,000 | 8,844,000 | 8,844,000 | 9,898,000 | 9,898,000 | 9,663,000 | 9,663,000 | 9,463,000 | 9,463,000 | 9,353,000 | 9,353,000 | 9,246,000 | 9,246,000 | 9,080,000 | 9,080,000 | 9,183,000 | 9,183,000 | 9,566,000 | 9,566,000 | 10,413,000 | 10,413,000 | 10,221,000 | 10,221,000 | 10,025,000 | 9,795,000 | 9,795,000 | 9,768,000 | 9,768,000 | 9,455,000 | 9,157,000 | 9,157,000 | 8,783,000 | 8,783,000 | 5,189,000 | |
capital reserve from employee benefits | 374 | 374 | 372,000 | 364,000 | 283,000 | 283 | 282 | 275,000 | 318 | 348,000 | 212,000 | 271,000 | -149,000 | -149,000 | -320,000 | -320,000 | -356,000 | -359,000 | -359,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | -337,000 | -337,000 | -337,000 | -337,000 | -337,000 | -337,000 | -337,000 | -337,000 | -81,000 | -81,000 | -81,000 | -81,000 | -81,000 | -81,000 | -81,000 | -59,000 | -59,000 | -59,000 | -59,000 | -59,000 | -81,000 | -81,000 | -129,000 | |
accumulated deficit | -20,636 | -25,932 | -33,308,000 | -25,738,000 | -29,546,000 | -33,409 | -37,835 | -40,200,000 | -45,258 | -48,484,000 | -51,428,000 | -51,912,000 | -47,991,000 | -46,163,000 | -41,154,000 | -41,246,000 | -55,855,000 | -61,073,000 | -61,073,000 | -66,435,000 | -66,435,000 | -72,258,000 | -72,258,000 | -78,401,000 | -78,401,000 | -83,024,000 | -83,024,000 | -100,769,000 | -100,769,000 | -98,378,000 | -98,378,000 | -104,064,000 | -104,064,000 | -104,563,000 | -104,563,000 | -110,815,000 | -110,815,000 | -110,579,000 | -110,579,000 | -115,441,000 | -111,464,000 | -111,464,000 | -109,656,000 | -109,656,000 | -108,615,000 | -104,731,000 | -104,731,000 | -92,884,000 | -93,461,000 | -80,248,000 | -80,248,000 |
total shareholder’s equity | 265,232 | 259,954 | 251,957,000 | 259,464,000 | 255,269,000 | 251,152 | 246,510 | 244,021,000 | 238,390 | 176,020,000 | 172,551,000 | 171,574,000 | 176,824,000 | 181,613,000 | 165,815,000 | 135,319,000 | 135,319,000 | 130,141,000 | 130,141,000 | 124,003,000 | 112,376,000 | ||||||||||||||||||||||||||||||
total liabilities and shareholder’s equity | 377,210 | 368,173 | 375,105,000 | 372,255,000 | 351,209,000 | 351,038 | 343,174 | 354,907,000 | 337,056 | 322,379,000 | 319,637,000 | 304,135,000 | 318,667,000 | 216,527,000 | 196,793,000 | 173,797,000 | 173,797,000 | 156,501,000 | 156,501,000 | 156,489,000 | 138,116,000 | ||||||||||||||||||||||||||||||
intangible assets, goodwill and other long-term assets | 99,640 | 135,041,000 | 136,830 | 138,623 | 140,465,000 | 142,501 | 147,072,000 | 148,620,000 | 150,449,000 | 151,858,000 | 153,663,000 | ||||||||||||||||||||||||||||||||||||||||
revenues from proprietary products | 78,453 | 25,317,000 | 47,662,000 | 20,381,000 | 47,646,000 | 38,192,000 | 12,214,000 | 50,568,000 | 33,510,000 | 6,636,000 | 38,270,000 | ||||||||||||||||||||||||||||||||||||||||
revenues from distribution | 10,319 | 7,973,000 | 14,388,000 | 6,416,000 | 18,612,000 | 13,091,000 | 5,227,000 | 16,547,000 | 10,687,000 | 5,012,000 | 14,966,000 | ||||||||||||||||||||||||||||||||||||||||
total revenues | 88,772 | 33,290,000 | 62,050,000 | 26,797,000 | 66,258,000 | 51,283,000 | 17,441,000 | 67,115,000 | 44,197,000 | 11,648,000 | 53,236,000 | ||||||||||||||||||||||||||||||||||||||||
cost of revenues from proprietary products | 40,580 | 14,947,000 | 25,178,000 | 10,490,000 | 30,506,000 | 22,648,000 | 6,179,000 | 32,727,000 | 21,218,000 | 5,165,000 | 23,843,000 | ||||||||||||||||||||||||||||||||||||||||
cost of revenues from distribution | 8,514 | 6,892,000 | 12,088,000 | 5,123,000 | 15,536,000 | 10,949,000 | 4,246,000 | 13,930,000 | 8,969,000 | 4,185,000 | 12,711,000 | ||||||||||||||||||||||||||||||||||||||||
total cost of revenues | 49,094 | 21,839,000 | 37,266,000 | 15,613,000 | 46,042,000 | 33,597,000 | 10,425,000 | 46,657,000 | 30,187,000 | 9,350,000 | 36,554,000 | ||||||||||||||||||||||||||||||||||||||||
gross profit | 39,678 | 11,451,000 | 24,784,000 | 11,184,000 | 20,216,000 | 17,686,000 | 7,016,000 | 20,458,000 | 14,010,000 | 2,298,000 | 16,682,000 | ||||||||||||||||||||||||||||||||||||||||
research and development expenses | 7,465 | 3,347,000 | 6,253,000 | 2,766,000 | 7,174,000 | 5,151,000 | 2,754,000 | 10,056,000 | 6,638,000 | 3,151,000 | 12,024,000 | ||||||||||||||||||||||||||||||||||||||||
selling and marketing expenses | 9,068 | 940,000 | 2,280,000 | 1,092,000 | 2,724,000 | 1,906,000 | 970,000 | 3,133,000 | 2,112,000 | 1,028,000 | 2,557,000 | ||||||||||||||||||||||||||||||||||||||||
general and administrative expenses | 8,265 | 2,312,000 | 4,621,000 | 2,094,000 | 6,132,000 | 4,230,000 | 2,064,000 | 6,270,000 | 3,947,000 | 1,830,000 | 5,688,000 | ||||||||||||||||||||||||||||||||||||||||
other incomes | 14 | 311,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
operating income | 14,866 | 4,850,000 | 11,602,000 | 5,209,000 | 3,875,000 | 6,399,000 | 1,228,000 | 999,000 | 1,313,000 | -3,711,000 | -3,587,000 | ||||||||||||||||||||||||||||||||||||||||
financial income | 987 | 317,000 | 547,000 | 280,000 | 628,000 | 414,000 | 229,000 | 266,000 | 174,000 | 78,000 | 388,000 | ||||||||||||||||||||||||||||||||||||||||
income (expenses) in respect of currency exchange differences and derivatives instruments | -723 | ||||||||||||||||||||||||||||||||||||||||||||||||||
financial expense in respect of contingent consideration and other long- term liabilities. | -2,380 | ||||||||||||||||||||||||||||||||||||||||||||||||||
financial expenses | -384 | -195,000 | -123,000 | -297,000 | -213,000 | -157,000 | |||||||||||||||||||||||||||||||||||||||||||||
income before tax on income | 12,366 | 5,624,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
taxes on income | -1,026 | 406,000 | 360,000 | 130,000 | -11,000 | -11,000 | 87,000 | 87,000 | 87,000 | 1,488,000 | |||||||||||||||||||||||||||||||||||||||||
net income | 11,340 | 5,218,000 | 11,066,000 | 4,923,000 | 4,551,000 | 6,942,000 | 1,256,000 | 649,000 | 885,000 | -3,977,000 | |||||||||||||||||||||||||||||||||||||||||
other comprehensive income : | |||||||||||||||||||||||||||||||||||||||||||||||||||
amounts that will be or that have been reclassified to profit or loss when specific conditions are met | |||||||||||||||||||||||||||||||||||||||||||||||||||
gain on cash flow hedges | 563 | 241,000 | 71,000 | 74,000 | -88,000 | -144,000 | -37,000 | 303,000 | |||||||||||||||||||||||||||||||||||||||||||
net amounts transferred to the statement of profit or loss for cash flow hedges | -158 | 34,000 | -2,000 | -2,000 | 34,000 | 7,000 | -21,000 | -219,000 | -116,000 | -22,000 | -71,000 | ||||||||||||||||||||||||||||||||||||||||
items that will not be reclassified to profit or loss in subsequent periods: | |||||||||||||||||||||||||||||||||||||||||||||||||||
remeasurement gain from defined benefit plan | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||
total comprehensive income | 11,755 | 5,332,000 | 11,284,000 | 5,075,000 | 4,496,000 | 6,776,000 | 1,169,000 | 748,000 | 1,153,000 | ||||||||||||||||||||||||||||||||||||||||||
earnings per share attributable to equity holders of the company: | |||||||||||||||||||||||||||||||||||||||||||||||||||
basic net earnings per share | 0.2 | ||||||||||||||||||||||||||||||||||||||||||||||||||
diluted net earnings per share | 0.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||
contract asset | 8,019,000 | 8,495,000 | 7,577,000 | 5,561,000 | |||||||||||||||||||||||||||||||||||||||||||||||
additional paid in capital | 266,588,000 | 210,005,000 | 179,589,000 | 179,589,000 | 179,471,000 | 179,471,000 | 179,352,000 | 179,352,000 | 178,873,000 | 178,873,000 | 178,745,000 | 178,745,000 | 178,458,000 | 178,458,000 | 177,874,000 | 177,874,000 | 162,671,000 | 162,671,000 | 162,238,000 | 162,238,000 | 158,417,000 | 158,417,000 | 157,100,000 | 157,100,000 | |||||||||||||||||||||||||||
current maturities of bank loans | 4,444,000 | 4,444,000 | 4,449,000 | 3,725,000 | 2,631,000 | 52,000 | 127,000 | 465,000 | 489,000 | ||||||||||||||||||||||||||||||||||||||||||
bank loans | 12,963,000 | 14,074,000 | 15,185,000 | 16,296,000 | 17,407,000 | 20,000 | 138,000 | 257,000 | 151,000 | ||||||||||||||||||||||||||||||||||||||||||
short-term investments | 48,038,000 | 47,124,000 | 31,245,000 | 31,245,000 | 39,380,000 | 39,380,000 | 38,122,000 | 38,122,000 | 33,800,000 | 33,800,000 | 32,499,000 | 32,499,000 | 32,051,000 | 32,051,000 | 32,233,000 | 32,233,000 | 30,451,000 | 30,451,000 | 30,338,000 | 30,338,000 | 27,986,000 | 27,986,000 | 15,906,000 | 15,906,000 | 17,865,000 | 18,664,000 | 18,664,000 | 20,722,000 | 20,722,000 | 22,391,000 | 23,259,000 | 23,259,000 | 37,350,000 | 37,350,000 | 15,067,000 | 15,067,000 | |||||||||||||||
shareholder's equity | |||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholder's equity | 175,150,000 | 181,220,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and shareholder's equity | 303,096,000 | 210,528,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
right-of-use-assets | 3,361,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
other long term assets | 3,380,000 | 3,175,000 | 1,053,000 | 352,000 | 352,000 | 178,000 | 178,000 | 174,000 | 174,000 | 174,000 | 174,000 | 174,000 | 174,000 | 176,000 | 176,000 | 173,000 | 173,000 | 173,000 | 173,000 | 49,000 | 49,000 | 370,000 | 370,000 | 89,000 | 179,000 | ||||||||||||||||||||||||||
deferred expenses | 421,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
capital reserve from financial assets measured at fair value through other comprehensive income | 145,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
other income | 2,000 | 23,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
income in respect of securities measured at fair value | 102,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
income in respect of currency exchange differences and derivatives instruments | 432,000 | -528,000 | -313,000 | 334,000 | 331,000 | -44,000 | |||||||||||||||||||||||||||||||||||||||||||||
financial expense | -77,000 | -50,000 | -36,000 | -23,000 | -106,000 | ||||||||||||||||||||||||||||||||||||||||||||||
gain from securities measured at fair value through other comprehensive income | -188,000 | 198,000 | 108,000 | -1,000 | -29,000 | -29,000 | |||||||||||||||||||||||||||||||||||||||||||||
tax effect | 27,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
basic income per share | 120 | 270 | 120 | 110 | 170 | 30 | |||||||||||||||||||||||||||||||||||||||||||||
diluted income per share | 120 | 270 | 120 | 110 | 170 | 30 | |||||||||||||||||||||||||||||||||||||||||||||
current maturities of bank loans and leases | 1,509,000 | 1,537,000 | 1,537,000 | 1,440,000 | 1,440,000 | 1,431,000 | 1,431,000 | ||||||||||||||||||||||||||||||||||||||||||||
bank loans and leases | 4,238,000 | 4,513,000 | 4,513,000 | 4,470,000 | 4,470,000 | 4,627,000 | 4,627,000 | ||||||||||||||||||||||||||||||||||||||||||||
capital reserve from securities measured at fair value through other comprehensive income | 145,000 | 137,000 | 137,000 | 187,000 | 187,000 | 118,000 | 118,000 | 34,000 | 34,000 | -33,000 | -33,000 | ||||||||||||||||||||||||||||||||||||||||
other incomes and | 28,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
income ( loss) before taxes | 11,426,000 | 4,540,000 | 6,931,000 | 1,256,000 | |||||||||||||||||||||||||||||||||||||||||||||||
items that may be reclassified to profit or loss in subsequent periods: | |||||||||||||||||||||||||||||||||||||||||||||||||||
actuarial gain from defined benefit plans | |||||||||||||||||||||||||||||||||||||||||||||||||||
income per share attributable to equity holders of the company: | |||||||||||||||||||||||||||||||||||||||||||||||||||
income before taxes | 5,053,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
current maturities of loans and capital leases | 562,000 | 562,000 | 585,000 | 585,000 | 588,000 | 588,000 | 609,000 | 609,000 | 614,000 | 614,000 | 412,000 | 412,000 | |||||||||||||||||||||||||||||||||||||||
loans and capital leases | 716,000 | 716,000 | 880,000 | 880,000 | 1,017,000 | 1,017,000 | 1,201,000 | 1,201,000 | 1,370,000 | 1,370,000 | 1,364,000 | 1,364,000 | |||||||||||||||||||||||||||||||||||||||
capital reserve from fair value financial assets through other comprehensive income | -5,000 | -5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
consolidated statements of profit or loss and other comprehensive income | |||||||||||||||||||||||||||||||||||||||||||||||||||
other comprehensive income | |||||||||||||||||||||||||||||||||||||||||||||||||||
capital reserve from available for sale financial assets | -33,000 | -33,000 | -4,000 | 34,000 | 34,000 | 31,000 | 31,000 | 37,000 | 19,000 | 87,000 | 87,000 | 119,000 | 73,000 | 10,000 | -27,000 | ||||||||||||||||||||||||||||||||||||
kamada ltd.'s shareholders' equity: | |||||||||||||||||||||||||||||||||||||||||||||||||||
ordinary shares of nis 1 par value: | |||||||||||||||||||||||||||||||||||||||||||||||||||
authorized - 70,000,000 ordinary shares; issued and outstanding – 40,262,819 and 36,419,842 shares at december 31, 2017 and 2016, respectively | 10,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
available for sale reserve | -4,000 | 19,000 | 73,000 | 10,000 | -27,000 | ||||||||||||||||||||||||||||||||||||||||||||||
shareholders' equity | |||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term assets | 443,000 | 443,000 | 404,000 | 404,000 | 372,000 | 71,000 | 71,000 | 73,000 | |||||||||||||||||||||||||||||||||||||||||||
current maturities of loans | 602,000 | 602,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
loans | 1,501,000 | 1,501,000 | 1,433,000 | 1,433,000 | 1,502,000 | 1,502,000 | 1,537,000 | 151,000 | |||||||||||||||||||||||||||||||||||||||||||
share premium | 177,193,000 | 177,193,000 | 162,686,000 | 162,686,000 | 162,686,000 | 162,649,000 | 162,649,000 | 162,649,000 | |||||||||||||||||||||||||||||||||||||||||||
income in respect of currency exchange and derivatives instruments | -479,000 | -479,000 | -132,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
gain before taxes on income | 736,000 | 972,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
other comprehensive income: | |||||||||||||||||||||||||||||||||||||||||||||||||||
gain on available for sale financial assets | 15,000 | 12,000 | 18,000 | 14,000 | |||||||||||||||||||||||||||||||||||||||||||||||
actuarial net gain of defined benefit plans | |||||||||||||||||||||||||||||||||||||||||||||||||||
basic earnings per share | 20 | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||
diluted earnings per share | 20 | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||
current maturities of loans and convertible debentures | 545,000 | 545,000 | 416,000 | 416,000 | 392,000 | 37,000 | |||||||||||||||||||||||||||||||||||||||||||||
profit on cash flow hedges | 372,000 | 207,000 | 124,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
current maturities of bank loans and capital leases | 437,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
long term loans and capital leases | 1,330,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
equity | |||||||||||||||||||||||||||||||||||||||||||||||||||
share capital | 9,321,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
income in respect of currency exchange and translation differences and derivatives instruments | -234,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
income before taxes on income | -3,890,000 | -3,437,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
other comprehensive loss: | |||||||||||||||||||||||||||||||||||||||||||||||||||
total comprehensive loss | -3,774,000 | -4,858,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
loss per share attributable to equity holders of the company: | |||||||||||||||||||||||||||||||||||||||||||||||||||
basic loss per share | -110 | -140 | |||||||||||||||||||||||||||||||||||||||||||||||||
diluted loss per share | -110 | -140 | |||||||||||||||||||||||||||||||||||||||||||||||||
ordinary shares of nis 1 par value: authorized - 60,000,000 ordinary shares; issued and outstanding – 36,447,175 and 36,418,741 shares at december 31, 2016 and 2015, respectively | 9,320,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
authorized - 60,000,000 ordinary shares; issued and outstanding – 36,447,175 and 36,418,741 shares at december 31, 2016 and 2015, respectively | 9,320,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
ordinary shares of nis 1 par value: authorized - 60,000,000 ordinary shares; issued and outstanding – 36,418,766 and 36,418,741 shares at september 30, 2016 and 2015, respectively. | 9,320,000 | 9,320,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
conversion option in convertible debentures | 1,147,000 | 1,147,000 | 2,218,000 | 2,218,000 | |||||||||||||||||||||||||||||||||||||||||||||||
loss | -4,925,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
ordinary shares of nis 1 par value: authorized - 60,000,000 ordinary shares; issued and outstanding – 36,418,741 and 36,387,929 shares at june 30, 2016 and 2015, respectively. | 9,320,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
long-term inventories | 85,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
long term assets | 89,000 | 179,000 | 165,000 | 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||
current maturities of convertible debentures and bank loans | 37,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
ordinary shares of nis 1 par value: authorized - 60,000,000 ordinary shares; issued and outstanding – 36,418,741 and 35,988,563 shares at december 31, 2015 and 2014, respectively | 9,320,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
note | |||||||||||||||||||||||||||||||||||||||||||||||||||
authorized - 60,000,000 ordinary shares; issued and outstanding – 36,418,741 and 35,988,563 shares at december 31, 2015 and 2014, respectively | 9,320,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
short term credit and current maturities of convertible debentures | 7,492,000 | 8,718,000 | 8,718,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
convertible debentures | 7,498,000 | 7,498,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
ordinary shares of nis 1 par value: authorized - 60,000,000 ordinary shares; issued and outstanding – 35,988,563 and 35,959,939 shares at december 31, 2014 and 2013, respectively | 9,208,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
current maturities of convertible debentures | 7,492,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
authorized - 60,000,000 ordinary shares; issued and outstanding – 35,988,563 and 35,959,939 shares at december 31, 2014 and 2013, respectively | 9,208,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||
authorized - 60,000,000 ordinary shares; issued and outstanding – 35,959,939 and 28,665,121 shares at december 31, 2013 and 2012, respectively | 9,201,000 | 9,201,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
other capital reserves | 5,060,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2025-03-05 | 2018-02-07 | 2017-02-06 | 2016-02-02 | 2015-02-11 | 2014-05-08 | 2014-02-05 |
|---|---|---|---|---|---|---|---|
cash flows from operating activities | |||||||
net income | 14,462,000 | 6,901,000 | -6,733,000 | -11,270,000 | -12,636,000 | 443,000 | |
adjustments to reconcile net income to net cash from operating activities: | |||||||
adjustments to the profit or loss items: | |||||||
depreciation and impairment | |||||||
financial expenses | 1,682,000 | 3,233,000 | |||||
cost of share-based payment | 874,000 | 483,000 | 1,071,000 | 1,907,000 | 3,751,000 | 1,327,000 | |
taxes on income | -1,128,000 | ||||||
loss from sale of property and equipment | 11,000 | -52,000 | -18,000 | -2,000 | 73,000 | ||
change in employee benefit liabilities | 52,000 | 166,000 | -87,000 | 87,000 | -57,000 | 121,000 | |
changes in asset and liability items: | |||||||
decrease in trade receivables | -1,977,000 | -9,967,000 | -3,445,000 | ||||
decrease in other accounts receivables | 593,000 | 328,000 | 211,000 | 118,000 | -50,000 | -911,000 | |
decrease in inventories | 9,659,000 | 4,524,000 | 742,000 | -913,000 | -3,490,000 | ||
decrease in deferred expenses | 594,000 | -433,000 | -565,000 | 1,209,000 | -1,231,000 | ||
increase in trade payables | 1,226,000 | -556,000 | -2,650,000 | 887,000 | 3,261,000 | 1,579,000 | |
increase in other accounts payables | 1,413,000 | 71,000 | 1,520,000 | 94,000 | -344,000 | ||
increase in deferred revenues | 23,000 | -2,930,000 | 1,035,000 | -2,405,000 | -4,125,000 | -6,270,000 | |
cash received during the period for: | |||||||
interest paid | -594,000 | -21,000 | -60,000 | -484,000 | -1,210,000 | -1,968,000 | |
interest received | 2,118,000 | 399,000 | 842,000 | 1,143,000 | 758,000 | 663,000 | |
taxes paid | -139,000 | -116,000 | -1,785,000 | -158,000 | -42,000 | ||
net cash from operating activities | 47,594,000 | ||||||
capital expenditures | -8,785,000 | ||||||
free cash flows | 38,809,000 | ||||||
cash flows from investing activities | |||||||
purchase of property and equipment and intangible assets | -10,740,000 | -4,449,000 | -2,641,000 | -2,718,000 | -3,076,000 | -5,643,000 | |
proceeds from sale of property and equipment | 1,000 | 60,000 | 42,000 | 3,000 | 8,000 | ||
net cash from investing activities | -10,739,000 | -3,903,000 | |||||
cash flows from financing activities | |||||||
proceeds from exercise of share base payments | 7,000 | ||||||
repayment of lease liabilities | -1,251,000 | ||||||
repayment of other long-term liabilities | -12,667,000 | ||||||
dividends paid | |||||||
net cash from financing activities | -13,911,000 | 15,320,000 | 1,490,000 | -6,355,000 | -7,640,000 | 49,208,000 | |
exchange differences on balances of cash and cash equivalent | -150,000 | -607,000 | -103,000 | -418,000 | |||
increase in cash and cash equivalents | 22,794,000 | 2,713,000 | 4,921,000 | -9,499,000 | -44,564,000 | 42,244,000 | |
cash and cash equivalents at the beginning of the period | |||||||
cash and cash equivalents at the end of the period | |||||||
significant non-cash transactions | |||||||
right-of-use asset recognized with corresponding lease liability | 3,304,000 | ||||||
● | |||||||
depreciation and amortization | 13,808,000 | 3,523,000 | 3,501,000 | 3,227,000 | 2,788,000 | 3,001,000 | |
proceeds from issuance of ordinary shares | 15,568,000 | 52,953,000 | |||||
repayment of long-term loans | |||||||
financial expense | 6,717,000 | ||||||
decrease in contract asset | 476,000 | ||||||
cash received during the year for: | |||||||
cash and cash equivalents at the beginning of the year | 55,641,000 | 9,968,000 | 5,047,000 | 14,546,000 | |||
cash and cash equivalents at the end of the year | 78,435,000 | 12,681,000 | 9,968,000 | 5,047,000 | |||
purchase of property and equipment in credit | 1,955,000 | ||||||
depreciation | |||||||
decrease in trade payables | |||||||
financial expenses (income) | 274,000 | -470,000 | -154,000 | ||||
decrease in other accounts payables | 731,000 | ||||||
decrease in deferred revenues | |||||||
gain from sale of property and equipment | |||||||
cash (paid) during the period for: | |||||||
business combination | |||||||
receipt of long-term loans | 279,000 | 1,701,000 | 197,000 | ||||
investment in short term investments | |||||||
cash paid during the year for: | |||||||
purchase of property and equipment | 1,681,000 | 1,968,000 | |||||
purchase of property and equipment through capital lease | 282,000 | 132,000 | |||||
financial income | |||||||
total adjustments | |||||||
increase in other accounts receivables | |||||||
increase in inventories | -1,182,000 | ||||||
decrease in contract asset and deferred expenses | |||||||
total changes in assets and liabilities | |||||||
proceeds of investment in short term investments | |||||||
receipt of long-term loan | |||||||
purchase of property and equipment through leases | |||||||
adjustments to reconcile net income to net cash (used in) provided by operating activities: | |||||||
increase in deferred expenses | |||||||
acquisition of subsidiary (llc) | |||||||
acquisition of subsidiary, net of cash | |||||||
repayment of long-term loans and leases | |||||||
depreciation, amortization and impairment | |||||||
decrease (increase) in deferred expenses | |||||||
income tax expense | 269,000 | 1,722,000 | 52,000 | 24,000 | |||
proceeds from sale of (investment in) short term investments | |||||||
increase (decrease) in deferred revenues | |||||||
proceeds from sale of )investment in) short term investments | |||||||
income tax expenses | |||||||
proceeds from exercise of options | 1,254,000 | ||||||
adjustments to reconcile net loss to net cash from operating activities: | |||||||
net cash fromoperating activities | 3,890,000 | 1,897,000 | -13,979,000 | -9,918,000 | |||
short-term investments | -11,501,000 | 4,236,000 | 13,971,000 | -23,746,000 | 38,811,000 | ||
net cash provided by investing activities | -15,890,000 | 1,627,000 | |||||
cash flows from finance activities | |||||||
proceeds from exercise of share base payment | 3,000 | ||||||
repayment long-term loans | -530,000 | -211,000 | -9,000 | ||||
proceeds from exercise of warrants and options | 88,000 | 562,000 | |||||
repayment of convertible debentures | -7,797,000 | -7,728,000 | -4,295,000 | ||||
net gain | |||||||
adjustments to reconcile gain to net cash from operating activities: | |||||||
depreciation, amortization and impairment of equipment | |||||||
finance expense ( income) | |||||||
decrease (increase) in trade receivables | |||||||
decrease (increase) in inventories | |||||||
cash received (paid) during the period for: | |||||||
net loss | |||||||
adjustments to reconcile loss to net cash from operating activities: | |||||||
loss | |||||||
finance expenses (income) | |||||||
cash paid and received during the period for: | |||||||
exercise of warrants and options into shares | |||||||
income from sale of property and equipment | |||||||
decrease (increase) in other accounts receivables | |||||||
increase in trade receivables | 3,489,000 | -5,604,000 | -1,347,000 | ||||
exercise of convertible debentures into shares | 7,000 | 6,507,000 | |||||
*represent an amount of less than 1 thousands | |||||||
finance income | |||||||
withholding taxes paid | -47,000 | ||||||
net cash frominvesting activities | 11,253,000 | -26,819,000 | |||||
note | |||||||
issuance expenses accrued in other accounts payable | 151,000 | ||||||
exercise of warrants presented as liability | 23,000 | ||||||
income from sale of fixed assets | |||||||
decrease (increase) in inventories and long-term inventories | |||||||
exercise of options into shares | |||||||
net cash provided (used in) by financing activities | |||||||
decrease in cash and cash equivalents | |||||||
finance expenses | |||||||
short term credit from bank and others | -12,000 | ||||||
restricted cash | |||||||
exch exchange differences on balances of cash and cash equivalent | -187,000 | 793,000 | |||||
cash and cash equivalents at the beginning of the year/period | 59,110,000 | 16,866,000 | |||||
cash and cash equivalents at the end of the year /period | 14,546,000 | 59,110,000 | |||||
purchase of property, plant and equipment and intangible assets on credit | |||||||
loss from sale of fixed assets | |||||||
decrease in inventories and long-term inventories | |||||||
proceeds from sale of equipment | |||||||
purchase of property, equipment and intangible assets on credit | |||||||
exercise of options presented as liability | |||||||
issuance expenses accrued in other accounts payables | |||||||
depreciation and amortization expense | |||||||
share-based compensation charges | |||||||
income in respect of translation differences and derivatives instruments | |||||||
one-time management compensation | |||||||
adjusted ebitda | |||||||
current assets | |||||||
cash and cash equivalents | 33,314,000 | ||||||
trade receivables | 12,592,000 | ||||||
other accounts receivables | 3,284,000 | ||||||
inventories | 28,614,000 | ||||||
non-current assets | |||||||
long-term inventories | |||||||
property, plant and equipment | 21,384,000 | ||||||
other long-term assets | 262,000 | ||||||
current liabilities | |||||||
short term credit and current maturities of convertible debentures | 8,678,000 | ||||||
trade payables | 16,321,000 | ||||||
other accounts payables | 3,750,000 | ||||||
deferred revenues | 5,431,000 | ||||||
non-current liabilities | |||||||
convertible debentures | 7,686,000 | ||||||
employee benefit liabilities | 801,000 | ||||||
equity | |||||||
share capital | 9,201,000 | ||||||
share premium | 157,117,000 | ||||||
conversion option in convertible debentures | 2,217,000 | ||||||
capital reserve due to translation to presentation currency | -3,490,000 | ||||||
capital reserve from hedges | 87,000 | ||||||
capital reserve from available for sale financial assets | 12,000 | ||||||
capital reserve from share-based payments | 6,266,000 | ||||||
capital reserve from employee benefits | -129,000 | ||||||
accumulated deficit | -83,370,000 | ||||||
net cash provided (used) by operating activities | -3,854,000 | ||||||
sale of short term investments | 1,732,000 | ||||||
decrease in material for clinical trials | |||||||
proceeds from sale of short term investments | |||||||
repayment of liabilities due to research and development grants | |||||||
purchase of property and equipment and intangible assets on credit | |||||||
adjustments to profit or loss items: | |||||||
increase in inventories and long-term inventories | |||||||
adjustments to reconcile loss to net cash provided by (used in) operating activities: | |||||||
7 |